Keyword: Nexavar

Transgene

7. Pexa-Vec

Given that backdrop of optimism in the oncolytic virus therapy category, the decision by French biotech Transgene and partner SillaJen to halt a trial of their oncolytic virus candidate Pexa-Vec (pexastimogene devacirepvec) in liver cancer was a warning about the potential pitfalls of this approach.